FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978179681> ?p ?o ?g. }

• W1978179681 endingPage "78S" @default.
• W1978179681 startingPage "72S" @default.
• W1978179681 abstract "Epidemiologic studies revealed that up to 10 percent of middle-aged men show more than 10 cessations of breathing of more than 10 seconds' duration. In these patients, increased morbidity and mortality rates have been proved. More than 50 percent of apnea patients exhibit arterial hypertension, and up to 50 percent of hypertensive patients experience sleep apnea. Patients with sleep apnea and essential hypertension need special attention paid to their antihypertensive therapy because the following side effects of drugs have to be avoided: increases of cardiac insufficiency, hyperviscosity of the blood, intensification of the hypersomnia by central sedation, intensification of a pre-existing tendency towards arrhythmias, and deprivation of deep and rapid eye movement sleep. In this study, the effects of angiotensin-converting enzyme inhibitors in patients with sleep apnea and hypertension are examined. An interim evaluation of six patients (aged 50 to 57) yielded the following results: Average Broca index, 124; average blood pressure before therapy, 159/102 mm Hg; average blood pressure after therapy, 132/78; a decrease of the apnea and hypopnea index from x = 31 (range, 12 to 77) to x = 20 (range, two to 54). Therapy did not influence sleep structure: before therapy, an average of 19 percent of sleep episodes were of the rapid eye movement type (range, 11 to 32 percent); after therapy, 23 percent were of this type on average (range, 21 to 25 percent). A final evaluation will be carried out after the second study phase for 12 patients who have been treated in a double-blind scheme with metropolol versus cilazapril. Epidemiologic studies revealed that up to 10 percent of middle-aged men show more than 10 cessations of breathing of more than 10 seconds' duration. In these patients, increased morbidity and mortality rates have been proved. More than 50 percent of apnea patients exhibit arterial hypertension, and up to 50 percent of hypertensive patients experience sleep apnea. Patients with sleep apnea and essential hypertension need special attention paid to their antihypertensive therapy because the following side effects of drugs have to be avoided: increases of cardiac insufficiency, hyperviscosity of the blood, intensification of the hypersomnia by central sedation, intensification of a pre-existing tendency towards arrhythmias, and deprivation of deep and rapid eye movement sleep. In this study, the effects of angiotensin-converting enzyme inhibitors in patients with sleep apnea and hypertension are examined. An interim evaluation of six patients (aged 50 to 57) yielded the following results: Average Broca index, 124; average blood pressure before therapy, 159/102 mm Hg; average blood pressure after therapy, 132/78; a decrease of the apnea and hypopnea index from x = 31 (range, 12 to 77) to x = 20 (range, two to 54). Therapy did not influence sleep structure: before therapy, an average of 19 percent of sleep episodes were of the rapid eye movement type (range, 11 to 32 percent); after therapy, 23 percent were of this type on average (range, 21 to 25 percent). A final evaluation will be carried out after the second study phase for 12 patients who have been treated in a double-blind scheme with metropolol versus cilazapril." @default.
• W1978179681 created "2016-06-24" @default.
• W1978179681 creator A5006677665 @default.
• W1978179681 creator A5007822217 @default.
• W1978179681 creator A5030296773 @default.
• W1978179681 creator A5032875352 @default.
• W1978179681 creator A5044400292 @default.
• W1978179681 creator A5048307428 @default.
• W1978179681 creator A5060022827 @default.
• W1978179681 creator A5080953778 @default.
• W1978179681 creator A5088964028 @default.
• W1978179681 date "1989-12-01" @default.
• W1978179681 modified "2023-09-23" @default.
• W1978179681 title "Effects of cilazapril on hypertension, sleep, and apnea" @default.
• W1978179681 cites W171779224 @default.
• W1978179681 cites W194887144 @default.
• W1978179681 cites W1968673910 @default.
• W1978179681 cites W1975244839 @default.
• W1978179681 cites W1979982893 @default.
• W1978179681 cites W2044058985 @default.
• W1978179681 cites W2061433606 @default.
• W1978179681 cites W229654734 @default.
• W1978179681 cites W2397690765 @default.
• W1978179681 cites W2470011045 @default.
• W1978179681 cites W2499722549 @default.
• W1978179681 cites W3022302886 @default.
• W1978179681 cites W336263197 @default.
• W1978179681 cites W419953555 @default.
• W1978179681 cites W2419253948 @default.
• W1978179681 doi "https://doi.org/10.1016/s0002-9343(89)80935-0" @default.
• W1978179681 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2532465" @default.
• W1978179681 hasPublicationYear "1989" @default.
• W1978179681 type Work @default.
• W1978179681 sameAs 1978179681 @default.
• W1978179681 citedByCount "13" @default.
• W1978179681 countsByYear W19781796812014 @default.
• W1978179681 countsByYear W19781796812015 @default.
• W1978179681 countsByYear W19781796812017 @default.
• W1978179681 countsByYear W19781796812022 @default.
• W1978179681 crossrefType "journal-article" @default.
• W1978179681 hasAuthorship W1978179681A5006677665 @default.
• W1978179681 hasAuthorship W1978179681A5007822217 @default.
• W1978179681 hasAuthorship W1978179681A5030296773 @default.
• W1978179681 hasAuthorship W1978179681A5032875352 @default.
• W1978179681 hasAuthorship W1978179681A5044400292 @default.
• W1978179681 hasAuthorship W1978179681A5048307428 @default.
• W1978179681 hasAuthorship W1978179681A5060022827 @default.
• W1978179681 hasAuthorship W1978179681A5080953778 @default.
• W1978179681 hasAuthorship W1978179681A5088964028 @default.
• W1978179681 hasConcept C126322002 @default.
• W1978179681 hasConcept C164705383 @default.
• W1978179681 hasConcept C27016395 @default.
• W1978179681 hasConcept C2777935920 @default.
• W1978179681 hasConcept C2779611605 @default.
• W1978179681 hasConcept C2781326671 @default.
• W1978179681 hasConcept C2781352967 @default.
• W1978179681 hasConcept C42219234 @default.
• W1978179681 hasConcept C71924100 @default.
• W1978179681 hasConcept C84393581 @default.
• W1978179681 hasConceptScore W1978179681C126322002 @default.
• W1978179681 hasConceptScore W1978179681C164705383 @default.
• W1978179681 hasConceptScore W1978179681C27016395 @default.
• W1978179681 hasConceptScore W1978179681C2777935920 @default.
• W1978179681 hasConceptScore W1978179681C2779611605 @default.
• W1978179681 hasConceptScore W1978179681C2781326671 @default.
• W1978179681 hasConceptScore W1978179681C2781352967 @default.
• W1978179681 hasConceptScore W1978179681C42219234 @default.
• W1978179681 hasConceptScore W1978179681C71924100 @default.
• W1978179681 hasConceptScore W1978179681C84393581 @default.
• W1978179681 hasIssue "6" @default.
• W1978179681 hasLocation W19781796811 @default.
• W1978179681 hasLocation W19781796812 @default.
• W1978179681 hasOpenAccess W1978179681 @default.
• W1978179681 hasPrimaryLocation W19781796811 @default.
• W1978179681 hasRelatedWork W2026207427 @default.
• W1978179681 hasRelatedWork W2065667239 @default.
• W1978179681 hasRelatedWork W2153979198 @default.
• W1978179681 hasRelatedWork W2164877549 @default.
• W1978179681 hasRelatedWork W2211841250 @default.
• W1978179681 hasRelatedWork W2353049249 @default.
• W1978179681 hasRelatedWork W2385997290 @default.
• W1978179681 hasRelatedWork W2413604339 @default.
• W1978179681 hasRelatedWork W2999510850 @default.
• W1978179681 hasRelatedWork W62060063 @default.
• W1978179681 hasVolume "87" @default.
• W1978179681 isParatext "false" @default.
• W1978179681 isRetracted "false" @default.
• W1978179681 magId "1978179681" @default.
• W1978179681 workType "article" @default.